Taurine 7 pp 85-93 | Cite as

Attenuating Action of Taurine and Labetalol on Cardiovascular Alterations by Pyridoxal-Isoproterenol, a Vitamin-Drug Interaction with Cardiopathologic Significance

  • Miteshkumar Acharya
  • Cesar A. Lau-Cam
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 643)


Taking into account the ability of vitamin B6 vitamers (i.e., pyridoxal, pyridoxine, pyridoxamine) to stimulate adrenomedullary catecholamine outflow and biochemical and cardiovascular changes consistent with adrenoceptor stimulation, this study was undertaken in mice to verify the possibility that pyridoxal (PL), the most potent of the B6 vitamers, could enter into an adverse vitamin-drug interaction when coadministered with a cardioactive drug, and that compounds like taurine (TAU) and labetalol (LAB) could be protective. To this end, mice were treated with PL (200 mg/kg) and isoproterenol (ISO 200 mg/kg), with and without a pretreatment with TAU (300 mg/kg), LAB (30 mg/kg), or TAU plus LAB, and monitored for heart rate, electrocardiographic (ECG) and myocardial electrolyte changes. PL plus ISO lowered the LD50 of ISO and magnified the changes in heart rate, ECG and myocardial electrolytes seen with ISO alone. Pretreating rats with TAU or TAU plus LAB attenuated the cardiovascular changes induced by PL plus ISO to a greater extent than LAB alone. The attenuating actions of TAU and LAB probably reflect independent and complementary mechanisms of action.


Lethal Dose Cardiac Change Phenobarbital Sodium Adrenoceptor Stimulation Cardioactive Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arnold LE (2001) Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann NY Acad Sci 931:310–341PubMedCrossRefGoogle Scholar
  2. Barletta MA, Lehr D, Guideri G (1978) Hemodynamic alterations in isoproterenol-induced myocardial cardiac arrhythmias in corticoid-treated rats. J Pharm Sci 67:1390–1394PubMedCrossRefGoogle Scholar
  3. Braunwald E (1971) Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol 27:416–432PubMedCrossRefGoogle Scholar
  4. Drew GM, Hilditch A, Levy GP (1979) The relationship between the cardiovascular effects, alpha- and beta-adrenoreceptor blocking actions and plasma concentration of labetalol in doca hypertensive rats. Clin Exp Hypertens 1:597–611PubMedCrossRefGoogle Scholar
  5. Furushima H, Chinushi M, Washizuka T, Aizawa Y (2001) Role of α-blockade in congenital long QT syndrome investigation by exercise. Jpn Circ J 65:654–658PubMedCrossRefGoogle Scholar
  6. Grubb BP (1991) The use of oral labetalol in the treatment of arrhythmias associated with the long QT syndrome. Chest 100:1724–1725PubMedCrossRefGoogle Scholar
  7. Guideri G, Barletta M, Lehr D (1974) Extraordinary potentiation of isoproterenol cardiotoxicity by corticoid pretreatment. Cardiovasc Res 8:775–786PubMedCrossRefGoogle Scholar
  8. Guideri G, Barletta M, Chau R, Green M, Lehr D (1975) Method for the production of severe ventricular dysrhythmias in small laboratory animals. Recent Adv Stud Cardiac Struct Metab 10:661–679PubMedGoogle Scholar
  9. Hoffman B, Lefkowitz R (1995) Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, McGraw-Hill, New York, pp 212–214Google Scholar
  10. Kleijnen J, Knipschild P (1991) Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry 29:931–941PubMedCrossRefGoogle Scholar
  11. Lau-Cam CA, Thadikonda KP, Kendall, BF (1991) Stimulation of rat liver glycogenolysis by vitamin B6: a role for adrenal catecholamines. Res Commun Chem Pathol Pharmacol 73:197–207PubMedGoogle Scholar
  12. Manger WM (1982) Catecholamines in normal and abnormal cardiac function. In: Kellerman JJ, Hashomer T (eds) Advances in cardiology, Karger Publishers, New York, pp 24–27Google Scholar
  13. Mitchell GF, Jeron A, Koren G (1998) Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 274 (Pt 2):H747–H751PubMedGoogle Scholar
  14. Nakagawa K, Kuriyama K (1975) Effect of taurine on alteration in adrenal functions induced by stress. Jpn J Pharmacol 25:737–746PubMedCrossRefGoogle Scholar
  15. Patel JP, Lau-Cam CA (2006) Taurine attenuates pyridoxal-induced adrenomedullary catecholamine release and glycogenolysis in the rat. In: Oja SS, Saransaari P (eds) Taurine 6, Springer, New York, pp 147–156CrossRefGoogle Scholar
  16. Read WO, Welty JD (1963) Effect of taurine on epinephrine and digoxin induced irregularities of the dog heart. J Pharmacol Exp Ther 139:283–289PubMedGoogle Scholar
  17. Saber S (1987) Elucidation of the mechanism of cardiotoxicity of vitamin B6 in rats, PhD Thesis, St John’s University, Jamaica, New YorkGoogle Scholar
  18. Satoh H, Sperelakis N (1998) Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol 30:451–463PubMedCrossRefGoogle Scholar
  19. Urao N, Shiraishi H, Ishibashi K, Hyogo M, Tsukamoto M, Keira N, Hirasaki S, Shirayama T, Nakagawa M (2004) Idiopathic long QT syndrome with early afterdepolarization induced by epinephrine. A case report. Circ J 68:587–591Google Scholar
  20. Welty MC, Welty JD, McBroom MJ (1982) Effect of isoproterenol and taurine on heart calcium in normal and cardiomyopathic hamsters. J Mol Cell Cardiol 14:353–357PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Miteshkumar Acharya
    • 1
  • Cesar A. Lau-Cam
  1. 1.Department of Pharmaceutical SciencesSt. John’s University College of Pharmacy and Allied Health ProfessionsJamaicaUSA

Personalised recommendations